MaxCyte Inc
LSE:MXCT
MaxCyte Inc
Revenue
MaxCyte Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MaxCyte Inc
LSE:MXCT
|
Revenue
$41.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Revenue
$42.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
13%
|
|
Danaher Corp
NYSE:DHR
|
Revenue
$43.7B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
9%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Revenue
$3.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
Agilent Technologies Inc
NYSE:A
|
Revenue
$6.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Revenue
$15B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
See Also
What is MaxCyte Inc's Revenue?
Revenue
41.3m
USD
Based on the financial report for Dec 31, 2023, MaxCyte Inc's Revenue amounts to 41.3m USD.
What is MaxCyte Inc's Revenue growth rate?
Revenue CAGR 5Y
20%
Over the last year, the Revenue growth was -7%. The average annual Revenue growth rates for MaxCyte Inc have been 16% over the past three years , 20% over the past five years .